PT2744826T - Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina - Google Patents

Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina

Info

Publication number
PT2744826T
PT2744826T PT127458834T PT12745883T PT2744826T PT 2744826 T PT2744826 T PT 2744826T PT 127458834 T PT127458834 T PT 127458834T PT 12745883 T PT12745883 T PT 12745883T PT 2744826 T PT2744826 T PT 2744826T
Authority
PT
Portugal
Prior art keywords
antibody
combination therapy
purine analog
purine
analog
Prior art date
Application number
PT127458834T
Other languages
English (en)
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PT2744826T publication Critical patent/PT2744826T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT127458834T 2011-08-16 2012-08-14 Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina PT2744826T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11177660 2011-08-16

Publications (1)

Publication Number Publication Date
PT2744826T true PT2744826T (pt) 2022-05-19

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127458834T PT2744826T (pt) 2011-08-16 2012-08-14 Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina

Country Status (23)

Country Link
US (2) US20140227277A1 (pt)
EP (2) EP2744826B1 (pt)
JP (1) JP6114273B2 (pt)
KR (3) KR20200060779A (pt)
CN (1) CN103703027B (pt)
AU (1) AU2012296905B2 (pt)
BR (1) BR112013033916B1 (pt)
CA (1) CA2841738C (pt)
DK (1) DK2744826T3 (pt)
ES (1) ES2909720T3 (pt)
HR (1) HRP20220224T1 (pt)
HU (1) HUE058855T2 (pt)
IL (1) IL230295B (pt)
LT (1) LT2744826T (pt)
MX (1) MX353589B (pt)
PL (1) PL2744826T3 (pt)
PT (1) PT2744826T (pt)
RS (1) RS63121B1 (pt)
RU (1) RU2664462C9 (pt)
SG (1) SG10201606788VA (pt)
SI (1) SI2744826T1 (pt)
WO (1) WO2013024095A1 (pt)
ZA (1) ZA201401835B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
CN106794231A (zh) * 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
AU2016266708B2 (en) 2015-05-26 2022-02-03 Incyte Corporation Combination of an anti-CD19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
WO2017032679A1 (en) 2015-08-21 2017-03-02 Morphosys Ag Combinations and uses thereof
JP7066639B2 (ja) * 2016-05-30 2022-05-13 モルフォシス・アーゲー 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
HUE054496T2 (hu) 2016-10-28 2021-09-28 Morphosys Ag CD19 elleni ellenanyag kombinálása BCL-2-gátlóval és alkalmazásuk
CN110678201A (zh) * 2017-05-31 2020-01-10 莫佛塞斯公司 抗cd19抗体和维奈托克组合治疗的治疗模式
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US11852A (en) 1854-10-31 Abraham bassford
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CN1689646A (zh) * 1998-08-11 2005-11-02 拜奥根Idec公司 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法
EP2289551A1 (en) 1999-06-09 2011-03-02 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) * 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EA200800094A1 (ru) 2005-06-20 2008-06-30 Медарекс, Инк. Антитела cd19 и их использование
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
KR101397290B1 (ko) * 2005-12-30 2014-05-21 메르크 파텐트 게엠베하 감소한 면역원성을 가지는 항-ｃｄ19 항체
DK2383297T5 (da) * 2006-08-14 2022-07-04 Xencor Inc Optimerede antistoffer rettet mod CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
WO2008150494A1 (en) * 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
PL2211904T3 (pl) 2007-10-19 2017-04-28 Seattle Genetics, Inc. Czynniki wiążące CD19 i ich zastosowanie
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2769595A1 (en) * 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
AU2010314905A1 (en) * 2009-11-06 2012-05-24 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
ZA201401835B (en) 2015-06-24
LT2744826T (lt) 2022-04-25
RS63121B1 (sr) 2022-05-31
KR20190094478A (ko) 2019-08-13
HRP20220224T1 (hr) 2022-04-29
KR20140071368A (ko) 2014-06-11
MX353589B (es) 2018-01-19
KR20200060779A (ko) 2020-06-01
DK2744826T3 (da) 2022-03-28
BR112013033916B1 (pt) 2022-11-16
BR112013033916A2 (pt) 2017-11-28
RU2664462C9 (ru) 2018-09-28
SI2744826T1 (sl) 2022-05-31
KR102117202B1 (ko) 2020-06-01
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
CA2841738C (en) 2022-12-06
IL230295B (en) 2018-03-29
AU2012296905B2 (en) 2017-01-05
CA2841738A1 (en) 2013-02-21
EP4083071A2 (en) 2022-11-02
EP2744826A1 (en) 2014-06-25
HUE058855T2 (hu) 2022-09-28
CN103703027A (zh) 2014-04-02
PL2744826T3 (pl) 2022-05-30
JP2014525925A (ja) 2014-10-02
EP2744826B1 (en) 2022-02-09
EP4083071A3 (en) 2023-02-22
US20140227277A1 (en) 2014-08-14
CN103703027B (zh) 2018-01-12
WO2013024095A1 (en) 2013-02-21
RU2014103490A (ru) 2015-09-27
RU2664462C2 (ru) 2018-08-17
NZ617771A (en) 2016-01-29
ES2909720T3 (es) 2022-05-10
JP6114273B2 (ja) 2017-04-12
US20200352975A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
ZA201401835B (en) Combination therapy with an anti-cd19 antibody and a purine analog
HK1202590A1 (en) Assays and methods for selecting a treatment regimen for a subject with depression and methods for treatment
DK2729170T3 (en) Antibody variants and uses thereof
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
EP2794654A4 (en) ANTI-PHF-TAU ANTIBODIES AND ITS USES
GB201110783D0 (en) Methods and uses
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
EP2694684A4 (en) SSO7 POLYMERASE CONJUGATES WITH REDUCED NON-SPECIFIC ACTIVITY
IL230293B (en) Combined treatment with anti-19cd antibody and nitrogen mustard
EP2688588A4 (en) FAST AND LONG-TERM IMMUNOLOGICAL THERAPEUTIC
GB201116774D0 (en) Uses and methods
IL224953A (en) Theobromine-containing preparations and their use in combination with a debilitating drug
EP2697386A4 (en) DESIGN AND USE OF PEPDUCINE
EP2676800A4 (en) ELEMENT WITH A CONCAVE PART AND MANUFACTURING METHOD THEREFOR
HK1172578A1 (en) Launcher toy and toy with the launcher toy
EP2721788A4 (en) METHOD AND ARRANGEMENT FOR SENDING QUESTIONS
HK1203232A1 (en) Biomarker and use thereof
AU339911S (en) A vehicle and a toy vehicle
GB201108490D0 (en) Methods and uses
ZA201401628B (en) Antiballistic article with resin
GB201114341D0 (en) Reagent and use
GB201119443D0 (en) GoWinging Concept and patent
IL215565A0 (en) Bed with accessible and usable space